Joint injections, used precisely, are a meaningful part of joint preservation. Used as a clinic category, endlessly repeated, sold by the syringe, they disappoint. The difference is in how the decision is made.
Used precisely, never as a marketing category.
The right injection, at the right time, into the right joint, inside a wider strategy.
Injections do four useful things, and one or two things they are wrongly asked to do. Knowing the difference is the work.
Role 01
A well-targeted injection can reduce symptoms enough that other parts of the preservation strategy, strength, biology, structured progression, can actually be done.
Role 02
A precisely placed local anaesthetic injection answers the question "is this pain really coming from here?" before larger decisions are made.
Role 03
PRP, PRF, and mFat give the joint a different chemical environment, modulating inflammation and supporting tissue repair where the conditions allow.
Role 04
For carefully selected arthritic joints, Arthrosamid can extend the preservation window by months or years.
Professor Lee was the first surgeon in the United Kingdom to use Arthrosamid, bringing the technique from Denmark, where it was first developed, into UK practice. Over five years and more than a thousand treated joints, that early adoption has matured into a specific injection protocol, refined from real-world outcomes rather than from a manufacturer briefing.
The Arthrosamid protocol Professor Lee uses today is not the protocol on the box. It is the result of careful patient selection, image-guided delivery, attention to the joint capsule and synovium, and decisions about combination therapy that have been refined over hundreds of cases. The same protocol now extends beyond the knee to selected hip, shoulder, ankle and other peripheral joint indications.
Among the patients who have publicly shared their story is Sharron Davies MBE, the Olympic medallist, treated by Professor Lee at London Cartilage Clinic with consent to be named. Sharron’s account, written in her own words and with supporting video, is the one named example here; most patients are kept anonymous as a matter of clinical practice. A named exception requires consent and is not the rule.
Provenance
Denmark to UK, first
Professor Lee introduced Arthrosamid into UK clinical practice from its country of development.
Volume and follow-up
Over a thousand joints, five years
A single-surgeon series spanning multiple joints, with longitudinal follow-up that informs current decision-making.
Beyond the knee
Selected hip, shoulder, ankle
The protocol now extends to other peripheral joints in carefully selected cases, outside the original knee indication.
Disclosure: London Cartilage Clinic (where Professor Lee performs Arthrosamid treatment) is a clinic Professor Lee founded. Research funding from Contura A/G, the manufacturer of Arthrosamid, supported a 2022 clinical study at MSK Doctors. Both disclosures are detailed on conflicts and disclosures.
These are different molecules, different biology, and different right answers. Treating them interchangeably, "just give me an injection", wastes the opportunity.
Synthetic hydrogel cushion. Sustained effect at multiple years in published follow-up.
Best for
Selected knees with osteoarthritis where pain is the dominant problem and the joint architecture is workable.
Not for
End-stage bone-on-bone with deformity, infection, or where surgery is clearly the right next step.
Patient-derived platelet concentrate. The best-evidenced of the autologous biologics.
Best for
Early-to-moderate arthritis, persistent tendinopathy, and as part of post-surgical biological optimisation.
Not for
A substitute for structural surgery in clearly mechanical problems.
A slower-release variant of platelet-rich therapy. Different preparation, different biology.
Best for
Cases where prolonged growth-factor release is the intended mechanism.
Not for
Conditions where PRP has stronger published evidence, the right preparation matters.
A patient's own fat tissue, mechanically processed, structural and biological support.
Best for
Carefully selected arthritic joints where a longer-acting biological cushion is appropriate.
Not for
Marketed as a "stem-cell injection", it is not. The honest framing is mechanical and biological support.
Every joint injection Professor Lee performs is image-guided. Ultrasound for most peripheral joints; fluoroscopy where deeper visualisation is needed. This is not a marketing claim, it is the default standard of practice in modern intervention-led care.
Blind injection misses the joint space in a non-trivial percentage of cases. When the injectate matters, especially for biologics and Arthrosamid, that miss rate is unacceptable.
Ultrasound guidance
Real-time imaging of the needle reaching its target. The default for most peripheral joint injections.
Fluoroscopic guidance
X-ray-based guidance for deeper joints (hip, spine), where ultrasound cannot reliably visualise the target.
No blind injection
Blind intra-articular injection misses the joint space in a meaningful percentage of cases. That is not a number worth accepting when imaging is available.
There is no single answer. The right injection depends on the joint, the stage of disease, the patient's goals, what has been tried before, and how the joint behaves at the time of assessment.
A specialist consultation is what allows that decision to be made well, not a price list of injection options to choose from.
No, and any practitioner suggesting that is overselling. What injections can do, used precisely, is delay surgery, support recovery from surgery, or, in the right cases, be the right intervention on their own. They are part of the toolkit, not the toolkit.
Arthrosamid: sustained effect at multiple years in published follow-up for appropriate candidates.
PRP / PRF: typically months, sometimes longer; often given as a planned series.
mFat: usually months to a year-plus; longer in many cases. All vary by joint, by stage of disease, and by what else is being done.
Sometimes one; sometimes a planned series. The strategy is set up front, including the question of when to stop, which is just as important as when to start. Injection therapy without a planned end-point tends to drift, and that is not how Professor Lee's practice works.
The pillar conversation injections sit inside, preservation before replacement, with Arthrosamid as a key bridging tool.
Read more
When the joint surface itself is the question, what scaffolds and reconstruction can and cannot do.
Read more
Injections are the input. Recovery is what determines whether the input becomes a result.
Read more
Used precisely, never as a marketing category
Arthrosamid, PRP, PRF, mFat, different molecules, different biology, different right answers. The work is in the decision-making, not the syringe.